Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This drug is generally administered once daily with the evening meal.
The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy:
When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin.
For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or the nearest therapeutically appropriate dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring.
This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months.
Elderly patients
Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).
Improves glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
blood sugar control issues
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is used to improve blood sugar control in adults with type 2 diabetes along with diet and exercise therapy, through the combination of dapagliflozin and metformin. It can be used especially in cases where blood sugar control is insufficient, among patients with cardiovascular disease or risk factors. However, it is advisable to refer to additional information from a specialist regarding the risk of cardiovascular events. Overall, this medication aids in blood sugar control and cardiovascular health management for patients with type 2 diabetes.
How to take
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This drug is generally administered once daily with the evening meal.
The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy:
When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin.
For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or the nearest therapeutically appropriate dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring.
This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months.
Elderly patients
Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).
Precautions
This medication contains two key components used to control blood sugar. The first component inhibits the reabsorption of sugar in the kidneys, helping to lower blood sugar by allowing sugar to be excreted in urine. The second component helps in blood sugar control by inhibiting sugar production in the liver and improving insulin sensitivity.
This medication should not be used in patients with renal impairment, dehydration, severe infections, cardiac disease, or during pregnancy and breastfeeding.
Serious metabolic complications such as severe lactic acidosis can occur rarely; therefore, if symptoms such as malaise, muscular pain, breathlessness, or abdominal pain appear during use, immediate consultation with a physician is necessary.
When taken with insulin or sulfonylureas, symptoms of hypoglycemia may occur, necessitating dosage adjustments.
During use, urinary tract and genital infections may occur, so prompt treatment should be sought for any infection symptoms.
Monitoring renal function regularly is crucial, as this medication may affect kidney function.
Excessive alcohol consumption may increase the risk of side effects.
It is advised to stop taking this medication for a certain period before and after surgery or radiographic contrast tests, and ensure renal function is normal before resuming.
This medication may cause a decrease in fluid volume and blood pressure, necessitating careful observation for especially elderly patients or those on diuretics.
Additionally, this medication may lower vitamin B12 levels; hence, checking vitamin B12 levels is recommended for long-term users.
Dizziness may occur while driving or operating machinery, so caution is advised.
Keep out of reach of children, and store it in its original container to maintain quality.
Side effects
severe lactic acidosis
severe hypoglycemia
vulvitis
balanitis
genital infections
urinary tract infections
fungal infections
hypoglycemia
reduced fluid volume
thirst
Show 82 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
low back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
elevated hematocrit
decreased renal creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
ketosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
vitamin B12 deficiency
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burns
wrist fractures
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland masses
toothache
headache
facial paralysis
peripheral neuropathy
sensory abnormalities
drowsiness
tremors
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
elevated alanine aminotransferase
increased blood glucose
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periarticular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
pruritus
benign prostatic hyperplasia
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
acute cholecystitis
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly closed container to protect it from air and moisture, preferably at a temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.
Appearance and packaging
Appearance
Yellow oval-shaped extended-release film-coated tablet with both sides convex
Package unit
30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.